Crystalline forms of compounds for targeted degradation of estrogen receptors

The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R, 2S)-6-hydroxy-2-phenyl-1, 2, 3, 4-tetrahydronaphthalene-1-yl) phenyl) piperidin-4-yl) methyl) piperazin-1-yl)-1-oxoisoindolin-2-yl) piperidin-2, 6-dione (Compound A), methods of preparing these polymorphic forms, and com...

Full description

Saved in:
Bibliographic Details
Main Authors HASKELL ROBERT JOHN III, RISSE HENDRIK, BURTON KEITH V, CHEN CHIEN-HUA
Format Patent
LanguageChinese
English
Published 04.07.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to polymorphic forms of (S)-3-(5-(4-((1-(4-((1R, 2S)-6-hydroxy-2-phenyl-1, 2, 3, 4-tetrahydronaphthalene-1-yl) phenyl) piperidin-4-yl) methyl) piperazin-1-yl)-1-oxoisoindolin-2-yl) piperidin-2, 6-dione (Compound A), methods of preparing these polymorphic forms, and compositions comprising these polymorphic forms. These polymorphic forms are useful in the treatment of various diseases, including, for example, breast cancer. 本公开涉及(S)-3-(5-(4-((1-(4-((1R,2S)-6-羟基-2-苯基-1,2,3,4-四氢萘-1-基)苯基)哌啶-4-基)甲基)哌嗪-1-基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮(化合物A)的多晶型形式、制备这些多晶型形式的方法和包括这些多晶型形式的组合物。这些多晶型形式可用于治疗各种疾病，包含例如乳腺癌。
Bibliography:Application Number: CN202180070126